Trial Profile

A planned registrational phase III trial of AE 37 in patients with breast cancer.

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 25 Apr 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AE 37 (Primary)
Indications Breast cancer
Focus Adverse reactions; Registrational; Therapeutic Use

Most Recent Events

31 May 2013 This trial is being prepared as part of a Special Protocol Assessment (SPA) with the US FDA, according to a Generex Biotechnology Corporation media release.
17 Jan 2013 Planned initiation date changed from 1 Jan 2013 to 1 Mar 2013; the FDA will accept submission of a phase III breast cancer trial protocol.
03 Jan 2012 Planned initiation date changed from 1 Jun 2013 to 1 Jun 2012, according to a Generex media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com